Announcements Trials
Browse Landscape

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 25Observational 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Renal Cell 5Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 2Urothelial Cancer 1

Interventions

atezolizumab 5avelumab 4erdafitinib 1enfortumab vedotin 1darolutamide 1Therapeutics 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Radiotherapy 1Patient Reported Outcome Measures 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immunotherapy 1Histocompatibility Testing 1High-Throughput Nucleotide Sequencing 1Hematologic Tests 1Gemcitabine 1Focus Groups 1Educational Status 1Drug Therapy 1Defecation 1Cytological Techniques 1Cystoscopy 1Cisplatin 1Carboxylesterase 1Blood Cell Count 1Biomarkers 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Carcinoma, Transitional Cell × avelumab × Clear all
NCT04822350 2026-04-02

AVENANCE

Pfizer

Completed
596 enrolled 43 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06412848 2026-02-24

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Active not recruiting
360 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05431777 2025-04-01

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
79 enrolled 20 charts
Genitourinary

Carcinoma, Transitional Cell

NCT05700344 2024-02-29

SOGUG

Spanish Oncology Genito-Urinary Group

Completed
125 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡